Danish pharmaceutical company Novo Nordisk has announced a new agreement with telehealth platform Hims & Hers Health aimed at expanding patient access to its FDA-approved semaglutide-based medicines in the United States. The partnership, which will take effect later this month, will allow patients using the digital healthcare service to obtain prescriptions for branded treatments including Ozempic and Wegovy.
Under the terms of the agreement, Hims & Hers will provide access to multiple dosage strengths of Ozempic injections and Wegovy in both injectable and oral tablet formulations. These medications will be offered to U.S. consumers through the telehealth platform at the same self-pay pricing levels that Novo Nordisk has established with other digital healthcare providers.
The collaboration also marks a shift in Hims & Hers’ approach to GLP-1 weight-loss therapies. The company will discontinue advertising compounded GLP-1 medications on its platform and in its marketing materials. Existing patients who previously used compounded formulations will have the option to transition to FDA-approved medicines, provided a healthcare professional determines it is clinically appropriate.
Novo Nordisk executives described the agreement as an important step toward improving patient access to scientifically validated treatments for diabetes and obesity. According to Mike Doustdar, expanding distribution through telehealth platforms can help connect more individuals with medications that have undergone rigorous regulatory review for safety and efficacy.
Doustdar emphasized that Wegovy represents more than a weight-loss therapy. Clinical studies have shown the drug can help adults with obesity lose significant weight while also reducing the risk of major cardiovascular events in patients who have established heart disease. This dual benefit—weight reduction combined with cardiovascular risk reduction—has helped distinguish the therapy in an increasingly competitive obesity treatment market.
Patients using the Hims & Hers platform will soon have access to the full range of semaglutide medicines offered by Novo Nordisk. These include injectable versions of Ozempic and Wegovy as well as the recently introduced oral Wegovy tablet. The medications are already widely available across the United States through more than 70,000 pharmacies, Novo Nordisk’s direct-to-consumer service NovoCare Pharmacy, and select digital healthcare providers.
Clinical evidence supporting the oral version of Wegovy includes results from the OASIS 4 trial. In that study, participants who used the medication alongside diet and exercise achieved an average weight loss of approximately 16.6 percent when all patients remained on treatment, compared with roughly 2.7 percent for those receiving placebo. When accounting for patients who discontinued treatment, average weight loss remained substantial at about 13.6 percent.
Common side effects observed in the trials included nausea, diarrhea and vomiting, which are consistent with those previously reported for injectable semaglutide therapies.
In addition to its obesity indication, Ozempic is approved for adults with type 2 diabetes to help improve blood sugar control and reduce the risk of cardiovascular events such as heart attack or stroke in patients with known heart disease.
As part of the agreement, Novo Nordisk also confirmed it will dismiss a previously filed patent infringement lawsuit against Hims & Hers, though the company noted it retains the right to refile the case if necessary in the future. The partnership reflects a broader effort by pharmaceutical companies and digital health providers to increase access to regulated, FDA-approved treatments as demand for GLP-1 medicines continues to grow rapidly in the United States.